データなし
コード銘柄名
現在値変化額変化率出来高売買代金始値前日終値高値安値時価総額浮動株時価株式総数浮動株5日変化率10日変化率20日変化率60日変化率120日変化率250日変化率年初来配当利回売買回転率直近PER前年PER振幅業種
お気に入り
データなし
Dermata Receives Approval From FDA For The Proprietary Name Xyngari For Its Phase 3 Acne Candidate
Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)".
Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement
8-K:Dermata Therapeuticsは、企業の最新情報を提供し、2024年第3四半期の決算を報告します
10-Q:Q3 2024 四半期報告書
Dermata Therapeutics Q3 EPS $(2.04) Beats $(2.64) Estimate